# Failure Analysis: Potential Pitfalls in NeuroGen Implementation

## 1. Data-Related Failures
### A. Domain Shift in Radiomics
*   **The Issue:** Radiomic features extracted from Siemens MRI scanners may not generalize to GE or Philips scanners due to variations in signal-to-noise ratios and pulse sequences.
*   **Mitigation:** Use Intensity Normalization (z-score) and White Stripe normalization. Implement Domain Adaptation techniques.

### B. Label Noise in Radiogenomics
*   **The Issue:** Molecular marker labels (IDH1, MGMT) are often determined by biopsy, which can have sampling errors. A tumor may be heterogeneous, with some regions mutated and others not.
*   **Mitigation:** Multi-rater consensus or Uncertainty Estimation (Monte Carlo Dropout). Provide confidence intervals for every molecular marker prediction.

## 2. Model-Related Failures
### A. "Clever Hans" Effect in Cross-Modal Attention
*   **The Issue:** The model might achieve high accuracy by looking at surgical staples, biopsy markers, or even the text overlays on DICOM images rather than the tumor itself.
*   **Mitigation:** Strict ROI (Region of Interest) cropping and rigorous XAI validation. Use Grad-CAM to verify the model is focusing on the tumor core.

### B. Radiomic Redundancy
*   **The Issue:** High-dimensional radiomic features are often highly correlated. This leads to overfitting.
*   **Mitigation:** Feature selection using LASSO or Principal Component Analysis (PCA). Use SHAP to identify the most influential radiomic features.

## 3. Clinical Integration Failures
### A. The "Black Box" Trust Gap
*   **The Issue:** Clinicians ignore accurate models if the "Why" is missing. A prediction of "Glioblastoma with IDH mutation" is meaningless without explaining which tumor regions triggered the classification.
*   **Mitigation:** Local Interpretable Model-agnostic Explanations (LIME) and providing confidence intervals for every prediction. Generate volumetric heatmaps for every diagnosis.

### B. False Positives in Rare Tumors
*   **The Issue:** The model may overfit to common tumor types (Glioma) and perform poorly on rare tumors (e.g., Lymphoma, Metastases).
*   **Mitigation:** Use class weights and focal loss. Implement uncertainty-aware rejection (do not predict when variance is high).
